Sanofi SA (SAN) Rating Reiterated by J P Morgan Chase & Co
Sanofi SA (EPA:SAN)‘s stock had its “neutral” rating restated by J P Morgan Chase & Co in a research note issued to investors on Thursday.
Other equities research analysts have also issued reports about the company. Deutsche Bank AG set a €96.00 ($110.34) price objective on Sanofi SA and gave the stock a “buy” rating in a research report on Thursday, March 30th. Morgan Stanley set a €91.00 ($104.60) price objective on Sanofi SA and gave the stock a “buy” rating in a research report on Wednesday, March 29th. Societe Generale set a €100.00 ($114.94) price objective on Sanofi SA and gave the stock a “buy” rating in a research report on Thursday, March 23rd. Berenberg Bank set a €92.00 ($105.75) price objective on Sanofi SA and gave the stock a “buy” rating in a research report on Friday, April 28th. Finally, Kepler Capital Markets set a €92.00 ($105.75) price objective on Sanofi SA and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of €88.19 ($101.36).
Shares of Sanofi SA (SAN) traded up 0.64% during trading on Thursday, reaching €82.77. The company’s stock had a trading volume of 1,301,166 shares. The stock has a market cap of €104.52 billion and a price-to-earnings ratio of 11.45. Sanofi SA has a 52-week low of €62.50 and a 52-week high of €92.97. The stock’s 50 day moving average price is €25.48 and its 200-day moving average price is €25.74.
COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/20/sanofi-sa-san-rating-reiterated-by-j-p-morgan-chase-co.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.